GB2357767B - Alzheimer's disease secretase app substrates therefor and uses therefor - Google Patents

Alzheimer's disease secretase app substrates therefor and uses therefor

Info

Publication number
GB2357767B
GB2357767B GB0023315A GB0023315A GB2357767B GB 2357767 B GB2357767 B GB 2357767B GB 0023315 A GB0023315 A GB 0023315A GB 0023315 A GB0023315 A GB 0023315A GB 2357767 B GB2357767 B GB 2357767B
Authority
GB
United Kingdom
Prior art keywords
therefor
alzheimer
app substrates
secretase app
disease secretase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0023315A
Other versions
GB2357767A (en
GB0023315D0 (en
Inventor
Michael Jerome Bienkowkski
Mark Gurney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/020881 external-priority patent/WO2000017369A2/en
Priority claimed from US09/416,901 external-priority patent/US6699671B1/en
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Priority to GB0125934A priority Critical patent/GB2367060B/en
Publication of GB0023315D0 publication Critical patent/GB0023315D0/en
Publication of GB2357767A publication Critical patent/GB2357767A/en
Application granted granted Critical
Publication of GB2357767B publication Critical patent/GB2357767B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
GB0023315A 1998-09-24 2000-09-22 Alzheimer's disease secretase app substrates therefor and uses therefor Expired - Fee Related GB2357767B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0125934A GB2367060B (en) 1999-09-23 2000-09-22 Alzheimer's disease secretase,app substrates therefor,and uses therefor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10159498P 1998-09-24 1998-09-24
US40413399A 1999-09-23 1999-09-23
US15549399P 1999-09-23 1999-09-23
PCT/US1999/020881 WO2000017369A2 (en) 1998-09-24 1999-09-23 Alzheimer's disease secretase
US09/416,901 US6699671B1 (en) 1998-09-24 1999-10-13 Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US16923299P 1999-12-06 1999-12-06

Publications (3)

Publication Number Publication Date
GB0023315D0 GB0023315D0 (en) 2000-11-08
GB2357767A GB2357767A (en) 2001-07-04
GB2357767B true GB2357767B (en) 2002-08-21

Family

ID=56290060

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0023315A Expired - Fee Related GB2357767B (en) 1998-09-24 2000-09-22 Alzheimer's disease secretase app substrates therefor and uses therefor

Country Status (1)

Country Link
GB (1) GB2357767B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0848062A2 (en) * 1996-12-14 1998-06-17 Smithkline Beecham Corporation Aspartic protease ASP1
DE19849073A1 (en) * 1998-10-24 2000-04-27 Aventis Pharma Gmbh Transgene encoding amyloid precursor protein or its fragment, used to produce transgenic nematodes used, e.g. to screen for agents for treating Alzheimer's disease
DE19910108A1 (en) * 1999-03-08 2000-09-21 Falk Fahrenholz Cells that co-express an amyloid precursor protein and an alpha-secretase, a test method for the identification of alpha-secretase-active substances and one for the identification of further secretases, a test method for determining the susceptibility to Alzheimer's disease and the use of nucleic acids which code for an alpha-secretase , for gene therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0848062A2 (en) * 1996-12-14 1998-06-17 Smithkline Beecham Corporation Aspartic protease ASP1
DE19849073A1 (en) * 1998-10-24 2000-04-27 Aventis Pharma Gmbh Transgene encoding amyloid precursor protein or its fragment, used to produce transgenic nematodes used, e.g. to screen for agents for treating Alzheimer's disease
DE19910108A1 (en) * 1999-03-08 2000-09-21 Falk Fahrenholz Cells that co-express an amyloid precursor protein and an alpha-secretase, a test method for the identification of alpha-secretase-active substances and one for the identification of further secretases, a test method for determining the susceptibility to Alzheimer's disease and the use of nucleic acids which code for an alpha-secretase , for gene therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. NEUROCHEM, 1998, 71, 1920-1925, GK GOURAS ET AL *

Also Published As

Publication number Publication date
GB2357767A (en) 2001-07-04
GB0023315D0 (en) 2000-11-08

Similar Documents

Publication Publication Date Title
GB2367060B (en) Alzheimer's disease secretase,app substrates therefor,and uses therefor
HUP0103838A3 (en) Alzheimer's disease secretase
PT1224297E (en) Alzheimer`s disease secretase, app substrates therefor, and uses therefor
EP1043991A4 (en) Treatment for alzheimer's disease
AU4208799A (en) Interleukins-21 and 22
HUP0103560A3 (en) Dolastatin 15 derivatives
EP1007048A4 (en) Identification of agents for use in the treatment of alzheimer's disease
AU3113500A (en) Compositions for treating alzheimer's disease and other amyloidoses
HUP0101799A3 (en) Integrated hydroconversion process
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
ZA978557B (en) Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.
PL332616A1 (en) Hydoxymethylhexanones as odorising and savourising agents
AU1405899A (en) Treatment for alzheimer's disease
GB2342182B (en) Ophthalmoscope and attachment therefor
PL350181A1 (en) Caspase−8 interacting proteins
GB2357767B (en) Alzheimer's disease secretase app substrates therefor and uses therefor
DE69908936D1 (en) 2''-deoxyhygromycinderivate
PL337368A1 (en) 13-dihydro-3'-azaridinoantracyclins
HUP9903516A3 (en) Countertops and method for it's mounting
GB9709206D0 (en) Artist's kit
GB9814045D0 (en) Alzheimer's disease
AU4518399A (en) Alzheimer's disease
AU2002301084A1 (en) Identification of agents for use in the treatment of alzheimer's disease
GB9808929D0 (en) Mothers' umbrella
GB9923706D0 (en) Sleep E's

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20110922